Together, we will produce the LTBI Diagnostic Kit here in Oman using ELISA technology, while jointly conducting research and development to transfer R-Biopharm’s advanced IP-10 technology onto our CLIA automation platform. This means the latest in diagnostic innovation will not only be developed but also manufactured locally, ensuring speed, quality, and independence for our region.
This achievement aligns with Oman Vision 2040 and supports national goals for economic diversification, technological advancement, sustainable healthcare, and national security — while strengthening our capacity to address urgent public health needs.
Our gratitude goes to:
- His Highness Sayyid Mohd Bin Salim Bin Ali Al Said.
- Her Excellency Dr. Rahma Bint Ibrahim Al Mahrouqi, Minister of Higher Education, Research, and Innovation (MOHERI).
- Our partners at R-Biopharm, especially Dr. Frank Vitzthum (Board Member, CTO) and Dr. Dirk Dressler (Head of TB Business Development) for their invaluable support and shared vision.
This is more than a business deal, it is a commitment to patients, healthcare professionals, and the next generation of scientists in our nations. The future we are building together starts today.
